In Alzheimer’s disease, some microglia gather around plaques, while others seem aloof, opting to keep their distance. In the July 14 Nature Neuroscience, scientists led by Marco Prinz at the ...

Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

Eight months after Eli Lilly reported that a more gradual titration for donanemab nearly halved the risk of ARIA-E, the U.S. Food and Drug Administration has given the modification the green light.

Discover a comprehensive list of brain banks worldwide, facilitating Alzheimer's and Parkinson's research on Alzforum.

Big Data Insights: Blood Signatures of Cognitive Decline, Aging, APOE4 RESEARCH NEWS 2025-07-23 Research News In the “omics” era, where bigger is better, the Global Neurodegeneration Proteomics ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a Phase 2 trial, donanemab completely cleared plaque in two-thirds of participants. Their cognitive decline slowed by a third, meeting the primary endpoint. The treatment appeared to nudge down ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

Brain Shuttle Sneaks Gantenerumab Past the Blood-Brain Barrier Initially, gantenerumab was nearly scuttled when low doses failed to budge endpoints in the Phase 3 Scarlet RoAD and Marguerite RoAD ...

Sasner sat down with Alzforum to go over what models are available now, which ones are coming, and how they could be used. The new mouse lines are the product of two different initiatives: NIA’s Model ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Results of the eagerly awaited Phase 3 clinical trial of LMTM, a derivative of the dye methylene blue, generated consternation at the Alzheimer’s Association International Conference 2016, held July ...